FDA approves Sun Pharma's generic Clarinex ANDA

NewsGuard 100/100 Score
Nov 18 2010

Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE:SUNPHARMA, BSE: 524715) announced that USFDA has granted it an approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Schering Plough's Clarinex® tablets, 5 mg.

These generic Clarinex tablets contain desloratidine 5 mg and are therapeutically equivalent to Schering Plough's Clarinex tablets 5mg.

Generic Clarinex tablets are indicated in the treatment of seasonal allergic rhinitis, perennial allergic rhinitis and Chronic idiopathic urticaria.

This strength of Clarinex® has annual sales of approximately $212 million in the US.

Source:

Sun Pharmaceutical Industries Ltd.

Posted in: Medical Condition News | Pharmaceutical News

Tags: , , , , , , , , , ,

Comments (0)

Suggested Reading

Supply chain assessment and management, optimizing pharmaceutical supply chains
Common HIV drugs linked to reduced Alzheimer's disease risk
Research confirms no association between SARS-CoV-2 and childhood asthma diagnoses
Lancet Commission predicts sharp increase in global prostate cancer cases
Food allergies' broad impact on quality of life demands greater awareness
New urine-based test improves identification of high-grade prostate cancer
Study highlights global fertility decline and its implications for the future
SCIEX’s Jose Castro-Perez Reveals How They're Setting New Standards in Mass Spectrometry

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
The Lancet Breast Cancer Commission: Tackling inequalities, hidden costs, and empowering patients